Celularity, Inc. (NASDAQ:CELU - Get Free Report) fell 3% during trading on Tuesday . The stock traded as low as $3.14 and last traded at $3.19. 134,420 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 580,949 shares. The stock had previously closed at $3.29.
Analysts Set New Price Targets
Separately, Wall Street Zen raised Celularity to a "sell" rating in a research report on Saturday.
Get Our Latest Stock Report on Celularity
Celularity Trading Down 4.9%
The company has a debt-to-equity ratio of 4.07, a quick ratio of 0.28 and a current ratio of 0.38. The company has a 50-day simple moving average of $2.30 and a 200 day simple moving average of $1.97. The company has a market capitalization of $74.72 million, a P/E ratio of -1.18 and a beta of 0.79.
Celularity (NASDAQ:CELU - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($1.50) by $0.91. Celularity had a negative return on equity of 271.88% and a negative net margin of 106.77%. The company had revenue of $18.13 million for the quarter, compared to analyst estimates of $5.20 million.
Institutional Trading of Celularity
Several institutional investors have recently modified their holdings of CELU. Biltmore Family Office LLC bought a new position in shares of Celularity during the 4th quarter worth approximately $73,000. Two Sigma Investments LP bought a new position in shares of Celularity during the 4th quarter worth approximately $93,000. Acadian Asset Management LLC bought a new position in shares of Celularity during the 1st quarter worth approximately $34,000. Finally, Valmark Advisers Inc. bought a new position in shares of Celularity during the 2nd quarter worth approximately $98,000. Institutional investors and hedge funds own 19.02% of the company's stock.
Celularity Company Profile
(
Get Free Report)
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.
Featured Stories
Before you consider Celularity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celularity wasn't on the list.
While Celularity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access